|
Originally published In Press as doi:10.1194/jlr.M200210-JLR200 on September 16, 2002
Journal of Lipid Research, Vol. 43, 2136-2145, December 2002
Copyright © 2002 by Lipid Research, Inc.
Overexpression of apoC-I in apoE-null mice
:
severe hypertriglyceridemia due to inhibition of hepatic lipase
Karin Conde-Knape*,
André Bensadoun ,
Joan H. Sobel*,
Jeffrey S. Cohn and
Neil S. Shachter1,*
* Department of Medicine, Columbia University, 630 W. 168th Street, New York, NY
Divisions of Nutritional and Biological Sciences, Cornell University, Ithaca, NY
Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, 110 Pine Avenue West, Montreal, Quebec, Canada
1 To whom correspondence should be addressed. e-mail: nss5{at}columbia.edu
Apolipoprotein C-I (apoC-I) has been proposed to act primarily via interference with apoE-mediated lipoprotein uptake. To define actions of apoC-I that are independent of apoE, we crossed a moderately overexpressing human apoC-I transgenic, which possesses a minimal phenotype in the WT background, with the apoE-null mouse. Surprisingly, apoE-null/C-I mice showed much more severe hyperlipidemia than apoE-null littermates in both the fasting and non-fasting states, with an almost doubling of cholesterol, primarily in IDL+LDL, and a marked increase in triglycerides; 3-fold in females to 260 ± 80 mg/dl and 14-fold in males to 1409 ± 594 mg/dl. HDL lipids were not significantly altered but HDL were apoC-I-enriched and apoA-II-depleted. Production rates of VLDL triglyceride were unchanged as was the clearance of post-lipolysis remnant particles. Plasma post-heparin hepatic lipase and lipoprotein lipase levels were undiminished as was the in vitro hydrolysis of apoC-I transgenic VLDL. However, HDL from apoC-I transgenic mice had a marked inhibitory effect on hepatic lipase activity, as did purified apoC-I. LPL activity was minimally affected. Atherosclerosis assay revealed significantly increased atherosclerosis in apoE-null/C-I mice assessed via the en face assay.
Inhibition of hepatic lipase may be an important mechanism of the decrease in lipoprotein clearance mediated by apoC-I.
Abbreviations: apo, apolipoprotein; apoE0, apoE gene knockout; Chol, cholesterol; CI, human apoC-I transgenic; E0CI, homozygous for the apoE0 allele and hemizygous for the human apoC-I transgene; HDL-C, HDL cholesterol; HL, hepatic lipase; LDLR, LDL receptor; LRP, LDL receptor-related protein Supplementary key words lipoproteins VLDL mutant strains

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
E. Anuurad, M. Yamasaki, N. Shachter, T. A. Pearson, and L. Berglund
ApoE and ApoC-I polymorphisms: association of genotype with cardiovascular disease phenotype in African Americans
J. Lipid Res.,
July 1, 2009;
50(7):
1472 - 1478.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Ruby, D. K. Nomura, C. S. S. Hudak, L. M. Mangravite, S. Chiu, J. E. Casida, and R. M. Krauss
Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride-rich lipoproteins
PNAS,
September 23, 2008;
105(38):
14561 - 14566.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. F. P. Berbee, S. P. Mooijaart, A. J. M. de Craen, L. M. Havekes, D. van Heemst, P. C. N. Rensen, and R. G. J. Westendorp
Plasma Apolipoprotein CI Protects Against Mortality From Infection in Old Age
J. Gerontol. A Biol. Sci. Med. Sci.,
February 1, 2008;
63(2):
122 - 126.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Zhang, R. Qi, X. Xian, F. Yang, M. Blackstein, X. Deng, J. Fan, C. Ross, J. Karasinska, M. R. Hayden, et al.
Spontaneous Atherosclerosis in Aged Lipoprotein Lipase-Deficient Mice With Severe Hypertriglyceridemia on a Normal Chow Diet
Circ. Res.,
February 1, 2008;
102(2):
250 - 256.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Gautier, U. J. F. Tietge, R. Boverhof, F. G. Perton, N. Le Guern, D. Masson, P. C. N. Rensen, L. M. Havekes, L. Lagrost, and F. Kuipers
Hepatic lipid accumulation in apolipoprotein C-I-deficient mice is potentiated by cholesteryl ester transfer protein
J. Lipid Res.,
January 1, 2007;
48(1):
30 - 40.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Freeman, M. J. A. Amar, R. Shamburek, B. Paigen, H. B. Brewer Jr., S. Santamarina-Fojo, and H. Gonzalez-Navarro
Lipolytic and ligand-binding functions of hepatic lipase protect against atherosclerosis in LDL receptor-deficient mice
J. Lipid Res.,
January 1, 2007;
48(1):
104 - 113.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Zschenker, T. Illies, and D. Ameis
Overexpression of lysosomal Acid lipase and other proteins in atherosclerosis.
J. Biochem.,
July 1, 2006;
140(1):
23 - 38.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Westerterp, W. de Haan, J. F. P. Berbee, L. M. Havekes, and P. C. N. Rensen
Endogenous apoC-I increases hyperlipidemia in apoE-knockout mice by stimulating VLDL production and inhibiting LPL
J. Lipid Res.,
June 1, 2006;
47(6):
1203 - 1211.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J. Wood, J. S. Volek, Y. Liu, N. S. Shachter, J. H. Contois, and M. L. Fernandez
Carbohydrate Restriction Alters Lipoprotein Metabolism by Modifying VLDL, LDL, and HDL Subfraction Distribution and Size in Overweight Men
J. Nutr.,
February 1, 2006;
136(2):
384 - 389.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. O. Kwiterovich Jr, S. L. Cockrill, D. G. Virgil, E. S. Garrett, J. Otvos, C. Knight-Gibson, P. Alaupovic, T. Forte, L. Zhang, Z. N. Farwig, et al.
A Large High-Density Lipoprotein Enriched in Apolipoprotein C-I: A Novel Biochemical Marker in Infants of Lower Birth Weight and Younger Gestational Age
JAMA,
April 20, 2005;
293(15):
1891 - 1899.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. F. P. Berbee, C. C. van der Hoogt, D. Sundararaman, L. M. Havekes, and P. C. N. Rensen
Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL
J. Lipid Res.,
February 1, 2005;
46(2):
297 - 306.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Namekata, Y. Enokido, I. Ishii, Y. Nagai, T. Harada, and H. Kimura
Abnormal Lipid Metabolism in Cystathionine {beta}-Synthase-deficient Mice, an Animal Model for Hyperhomocysteinemia
J. Biol. Chem.,
December 17, 2004;
279(51):
52961 - 52969.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Conde-Knape, K. Okada, R. Ramakrishnan, and N. S. Shachter
Overexpression of apoC-III produces lesser hypertriglyceridemia in apoB-48-only gene-targeted mice than in apoB-100-only mice
J. Lipid Res.,
December 1, 2004;
45(12):
2235 - 2244.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J. Brown, A. Gauthier, R. J. Parks, R. McPherson, D. L. Sparks, J. R. Schultz, and Z. Yao
Severe Hypoalphalipoproteinemia in Mice Expressing Human Hepatic Lipase Deficient in Binding to Heparan Sulfate Proteoglycan
J. Biol. Chem.,
October 8, 2004;
279(41):
42403 - 42409.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Kolmakova, P. Kwiterovich, D. Virgil, P. Alaupovic, C. Knight-Gibson, S. F. Martin, and S. Chatterjee
Apolipoprotein C-I Induces Apoptosis in Human Aortic Smooth Muscle Cells via Recruiting Neutral Sphingomyelinase
Arterioscler. Thromb. Vasc. Biol.,
February 1, 2004;
24(2):
264 - 269.
[Abstract]
[Full Text]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|